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INTRODUCTION 
Cardiac myocytes stop dividing shortly after birth and subsequently the heart 
grows by enlargement of individual cells, a process that can be observed in vitro 
as well.' However, growth of individual cardiomyocytes can also be observed in 
the adult heart, a process called hypertrophy. Chronic hernodynamic overload of 
the heart by, e.g. ,  infarction, hypertension or volume or pressure overload ulti- 
mately leads to hypertrophy of the left ventricular wall. The hypertrophy process 
involves induction of transcription of specific contractile as well as noncontractile 
protein genes resulting in growth as well as change in contractile function of the 
c a r d i o r n y o ~ y t e . ~ ~ ~  This allows the heart to maintain normal beat-to-beat volume 
under the circumstances mentioned above. Although only limited evidence was 
presented for their importance during in vivo development of hypertr~phy,~-' hor- 
monal and mechanical stimuli are thought to be the initial signals that trigger the 
onset of cell growth. The evidence for the involvement of hormonal and mechani- 
cal signals in the induction of hypertrophy mainly comes from in vitro models 
employing cultured neonatal cardiomyocytes. Here it was shown that induction 
of hypertrophy is accompanied by activation of the phosphoinositide (PI) cycle 
and by rapid stimulation of transcription of so-called immediate early genes, tran- 
scription factors, ultimately leading to rearrangement of gene expression of struc- 
tural proteins in the cardiomyocyte. Recently, studies of hypertrophy were also 
performed on cultured adult cardiomyocytes,8-'1 confirming results from the neo- 
natal cardiomyocyte model. In this review we focus on the influence of these 
hormonal and mechanical signals that activate the PI cycle during development 
of hypertrophy in the model of cultured cardiomyocytes and the ultimate outcome 
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of hypertrophic stimulation for the cardiac myocyte. The last section deals with 
some of our most recent results. 
Some of the signals that trigger a hypertrophic response are not transduced 
through activation of the PI pathway. These include P-adrenergic stimulation that 
activates adenylate cyclase,I2 while several growth factors like fibroblast growth 
factor,l3.l4 insulin-like growth f a ~ t o r - I , ’ ~ , I ~  thyroid hormone and transforming 
growth factor PI3 were also shown to activate growth-like responses. Extracellular 
signals that stimulate the PI cycle can also lead to growth of the cardiomyocyte, 
and in the last years more and more agonists of this type were identified. These 
include the al -adrenergic agonist phenylephrine (PHE),” angiotensin I1 (AngII),I8 
end~thelin-l(ET-l)’~,~’ and a-thrombin.21 Furthermore, stretching of cultured 
cardiomyocytes leads to increased PI cycle activity and ultimately to hypertro- 
phy.2* Increased contractile activity of cardiomyocytes also induces hypertro- 
phy,23.24 but the question might be asked whether this is an independent mecha- 
nism or is transduced through increased stretching of the cells. We might even 
envisage P-adrenergic induction of hypertrophy as being partly the result of an 
increase in beating frequency of the myocytes. 
Stimulation by LYI -Adrenergic Agonist 
aI -Adrenergic stimulation of phosphoinositide hydrolysis in cardiomyocytes is 
mediated through the alA-adrenergic receptor2’ that is coupled to phospholipase 
Cp through the GTP-binding protein Gq,l I .*6 Blocking the alA-adrenergic receptor 
led to inhibition of cq-induced hypertrophy, in contrast to treatment with aIs-  
adrenergic receptor blockers.2s Blocking the Gq,l I function results in inhibition of 
aI  -adrenergic-mediated hypertrophy as These results directly implicate the 
PI cycle as an important intermediate in the signal transduction cascade leading 
to induction of cell growth. However, we have to be aware of the fact that at- 
adrenergic agonist is translocated to the nucleus where the receptor is also local- 
ized,*’ suggesting a direct role of the receptor-agonist complex in regulation of 
gene expression. More distal elements of the signaling cascade involved in hyper- 
trophy induction by catecholamines have also been identified. a1 -Adrenergic stim- 
ulation of cardiomyocytes results in increased diacylglycerol Probably 
as a result of this, activation and translocation of protein kinase C to membranes 
and myofilaments  occur^.^^-^^ Activation of protein kinase C by phorbol ester 
is sufficient to give several hypertrophic  response^,^^,^^,^^ as was also elegantly 
demonstrated by protein kinase C transfection However, activation 
of protein kinase C is not the only factor involved in induction of hypertrophy, 
Taking expression of atrial natriuretic factor (ANF) as parameter of the degree of 
hypertrophy (see below), it was shown that inhibition of protein kinase C activity 
resulted in a 75% decline in hypertrophic response to a1 -adrenergic stimulation.28 
On the other hand, inhibition of Ca’ +/calmodulin-regulated kinases completely 
blocked development of hypertrophy, in agreement with the requirement for cal- 
cium of the hypertrophy process. The involvement of Ca2 + /calmodulin-regulated 
processes in induction of cell growth is further substantiated by a study in which 
overexpression of calmodulin led to induction of hypertrophy as well as hyperpla- 
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~ i a . ~ ~  Other kinases that might be involved in transduction of the extracellular 
signal to the nucleus are MAP(kinase) kinases, which are thought to play an impor- 
tant role in growth-related processes. These MAP(kinase) kinases are activated 
by -adrenergic stimulation of c a r d i o m y ~ c y t e s . ~ ~  However, direct evidence for 
the involvement of MAP kinases in the signaling pathway connecting the a1 -adren- 
ergic receptor to nuclear events has not been obtained. Coordinated expression of 
several genes takes place as a result of LYI -adrenergic stimulation. The hypertrophic 
response after a, -adrenergic stimulation was inhibited by mutated, inactive Hras 
proto-~ncogene’~ suggesting that tyrosine kinases are involved in this response, 
independent of activation of the PI cycle? Early and transient responses include 
transcription of so-called immediate early genes, encoding known or putative tran- 
scription factors. The first proto-oncogene that was shown to be induced by a1- 
adrenergic stimulation was c - m y ~ . ~ ~  However, constitutive overexpression of c- 
myc in a strain of transgenic mice did not lead to a hypertrophic response but led 
to growth of the heart by hyperplasia suggesting that it is not directly involved in 
growth of the heart by cell er~largement.~’ Other proto-oncogenes that are ex- 
pressed upon a,-adrenergic stimulation are c-fos, c-jun and EGR-I .42 The c-fos/ 
c-jun heterodimer binds to AP-1 DNA consensus sequences resulting in activation 
of transcription of genes containing these elements, e .g . ,  in the ANF gene.43 The 
presence of EGR-I protein is a prerequisite for agonist-induced h y p e r t r ~ p h y ~ ~  as 
will be discussed below for ET- 1. At a later stage of hypertrophy, protein synthesis 
 increase^,'^,^^,^^ accompanied by enhanced transcription of several genes. These 
include the contractile protein myosin light chain-2 that is assembled into organ- 
ized sarcomeric ~ n i t s . ~ ~ , ~ *  However, embryonic genes ANF,2s,48,49 skeletal a- 
actin50-52 and P-myosin heavy were induced as well resulting in a change 
in phenotype of the cardiomyocyte. This change is further reflected by a lack of 
induction of cardiac Naf channel e x p r e s ~ i o n . ~ ~  
Stimulation by ET-I 
Stimulation of cardiomyocytes with ET-1 results in activation of phospholipase 
C, as was the case for PHE, again leading to increased inositolphosphate produc- 
t iod4  and diacylglycerol levels. 19,29 This effect is probably mediated by the ET- 
A r e ~ e p t o r . ~ , ’ ~ . ~ ~  Given the important role of the PI cycle in activation of the 
hypertrophy process,” it is not surprising to see that the hypertrophic responses 
of ET-1 and PHE are remarkably similar. After stimulation with ET-1, protein 
kinase C is activated33 as well as MAP(kinase) k i n a ~ e ~ ~  and MAP k i n a ~ e . ~ ~ , ~ ~  The 
activation of protein kinase C by ET-1 is necessary for induction of hypertrophy 
as judged by inhibition of ET-1-induced increase in protein synthesis after incuba- 
tion with a protein kinase C inhibitor.” Activation of MAP kinase is partly brought 
about by the activity of protein kinase C isotypes that are stimulatable by phorbol 
ester. However, as downregulation of these isozymes by prolonged incubation of 
cultured cardiomyocytes with phorbol ester did not result in total inhibition of 
ET-1-induced MAP kinase activity,” this hormone might also activate so-called 
atypical protein kinase C isozymes that do  not require Ca2+ and/or diacylglycerol 
for activation. Moreover, as cultured cardiomyocytes contain protein kinase 
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C-(Y and -6,57 isozymes that are not found in the intact adult heart,33 the relative 
importance of both signaling pathways remains to be determined. As was the case 
for al -adrenergic stimulation, incubation with ET-I activates the immediate early 
gene program. Here, c-fos and EGR-1 were induced within 30 min after stimulation 
and decreased again after 1 h o ~ r . ’ ~ , ’ ~ , ~ ~  The expression of EGR-1 is of prime 
importance for development of hypertrophy: blocking translation of the EGR-1 
mRNA by an antisense oligonucleotide completely inhibits ET-I -induced stimula- 
tion of protein synthesis, an  indicator of h y p e r t r ~ p h y . ~ ~  Rearrangement of gene 
expression was again noticed: the transcription of the embryonic gene ANF‘9.29 
as well as of the a-actin, and troponin I genes were stimulated.60 Myosin light 
chain-2 gene transcription was also stimulated,60 and increased amounts of myosin 
light chain-2 were assembled into organized contractile units.” In contrast to a I -  
adrenergic stimulation, ET-1 not only increased transcription of the embryonic 
myosin heavy chain P-isozyme but also of the adult a-form.6’ This suggests that 
differences in signal transduction pathways leading to hypertrophy exist between 
the al-adrenergic agonist and ET-1. It was already shown that exposure of cardio- 
myocytes leads to partial homologous desensitization of the PI cycle activity, a 
phenomenon not present during a ,  -adrenergic ~ t i m u l a t i o n . ~ ~ . ~ ~  Whether this is the 
underlying mechanism that is responsible for the difference in myosin heavy chain 
isozyme expression as described above and the rapid decrease of ET-1-induced 
ANF mRNA levels29 remains to be determined. During development of hypertro- 
phy the amount of RNA in the cells increases as well as protein synthesis.’’.20. 
58m Conflicting results were reported concerning the role of extracellular Ca2 + 
in stimulation of protein synthesis by ET-1. In one study, a Ca2+ blocker had no 
effect,m while the group of Suzuki and co-workers showed that the same Ca2+ 
channel blocker partly inhibited ET- 1-induced increase in protein s y n t h e s i ~ . ~ ~ . ~ ~  
On the other hand, it was shown that an increase in intracellular Ca2+ leads to a 
temporal stimulation of transcription of the myosin light chain-2, a-actin and tropo- 
nin genes,60 while ET-1-stimulated ANF release was also partially Ca2+ depen- 
dent.62 Together with the results concerning Ca2 + dependence of the a’-adrenergic 
induction of hypertrophy, we would like to suggest that Ca2+ is also important 
for ET-1-induced hypertrophy. In this respect it is interesting to note that we 
recently showed that intracellular free Ca2+ has a feed-forward stimulatory effect 
on phospholipase C when the enzyme is stimulated with ET-1 or PHE.63 Although 
it is thought that endothelial cells are the major source of endothelin, it is important 
to mention that ET-1 is produced and secreted by cardiomyocytes as sug- 
gesting that autocrine/paracrine mechanisms of induction of hypertrophy might 
be important too. 
Stimulation by Angll 
Another peptide hormone that was shown to induce hypertrophy is AngII,4.’8 
acting through the AT1 re~ep to r .~ ’  AngII provokes phospholipase C activity that 
is rapidly de~ens i t i zed .~~ .~ ’  However, the increase in DAG is more prolonged, and 
it was shown that AngII also activates phospholipase D resulting in degradation 
of phosphatidylcholine and formation of diacylglycerol through phosphatidic 
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a ~ i d . ~ ~ , ~ ~  Probably as a result of this, protein kinase C is activated. Furthermore, 
cyclic-AMP levels were increased and arachidonic acid production was stimulated 
showing that Angll activates several signal transduction pathways at the same 
time. As a result of protein kinase C activation the expression of c-fos was tran- 
siently stimulated in a Ca2+-dependent manner. The immediate early genes c- 
jun, jun-B, EGR-1 and c-myc were also transiently e x p r e s ~ e d . ~ . ' ~ , ~ ~  Again, the 
expression of embryonic genes was induced; ANF as well as skeletal a-actin 
mRNA was increased within 6 hrs of stimulation with AngII. As research into 
the hypertrophic effect of AnglI is relatively young, studies on expression of 
contractile genes are not yet available. We have to keep in mind that prolonged 
incubation of cardiomyocytes leads to stimulation of ET- 1 synthesis and secretion 
by ca rd iomyocy te~ .~~  This opens the possibility that part of the Angll-mediated 
responses are brought about by ET-1. 
Stretching of cardiomyocytes also results in activation of phospholipase C and 
phospholipase D, and release of arachidonic acid and ultimately leads to hypertro- 
phy.70-74 This is preceded by a short-lived increase in the inositolphosphate level 
and prolonged diacylglycerol accumulation, as well as protein kinase C and MAP 
kinase a~tivation.~'  The MAP kinase activation was partially dependent on Ca2+ 
and the presence of phorbol ester-stimulatable protein kinase C,73,75 and although 
tyrosine kinases were activated,73 they were not involved in activation of MAP 
kina~es:~ suggesting a dual pathway of activation and a role for atypical protein 
kinase C isozymes. The immediate early gene c-fos was induced in a protein kinase 
C-dependent manner,73 and c-jun, c-myc and EGR-1 were induced as  ell.^.^' At 
a later stage of hypertrophy induction, the fetal cardiac genes ANF, p-MHC and 
skeletal a-actin were e ~ p r e s s e d . ~ '  These data are reminiscent of the multiple path- 
ways that are activated by AngII and it was indeed shown that upon stretch, Angll 
is released by cardiomyocytes in c u l t ~ r e . ~ ~ , ~ ~  The involvement of Angll in stretch- 
induced hypertrophy was confirmed by a study where stretch-induced hypertro- 
phy could be blocked by an AngIl receptor a n t a g ~ n i s t . ~  Furthermore, ion-channels 
and contractile activity were shown not to be involved in transduction of stretch- 
signals to the nucleus.78 The control of gene expression during mechanical stress 
was recently reviewed.79 At this stage it is important to stress again that AngIl 
also has an effect on ET-1 levels; AngII induces ET-1 precursor mRNA in cardio- 
myocytes in a protein kinase C-dependent fashion.69 This depicts a situation where 
stretching of the cardiomyocytes directly activates multiple signaling pathways 
through the stretch-induced release of AnglI followed by activation of phospholi- 
pase C by ET-1 that is produced and released by cardiomyocytes under influence 
of AngII. 
Stimulation by Thrombin 
A fourth receptor that is coupled to induction of hypertrophy through activation 
of the PI cycle is the thrombin receptor.21.80 Actually, it is a receptor for its own 
N-terminal peptide that is cleaved from the receptor by thrombin. Stimulation of 
cardiomyocytes with thrombin as well as with the N-terminal peptide leads to 
morphological and genetic changes that are reminiscent of hypertrophy: cells are 
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enlarged and contain highly organized sarcomeric units while ANF expression is 
induced in a dose-dependent manner. The signal transduction pathway involves 
both protein kinase C and tyrosine kinase activation. The relative importance of 
thrombin in in vivo induction of hypertrophy remains to be determined as cardio- 
myocytes are normally separated from circulating thrombin by the vessel wall. 
Other Stimuli 
We have to be aware of the fact that activation of phospholipase C not only 
occurs through G-protein-coupled receptors, but that tyrosine kinases can also 
lead to increased PI cycle activity through phosphorylation and activation of the 
phospholipase C y-isozyme. Tyrosine kinase activity is an inherent property of a 
large amount of receptors, e . g . ,  the EGF, insulin, and FGF receptor families.81 
Indeed, FGF activates tyrosine kinases and MAP kinases5’ and induces hypertro- 
phy. I 3 , l 4  Whether other receptor tyrosine kinases also induce hypertrophy remains 
to be determined. Hypertrophic responses like induction of ANF expression and 
stimulation of myosin light chain-2 gene expression can also be brought about by 
electrical stimulation of contraction of cardiac myocytes, independent of activa- 
tion of protein kinase C or A but depending on Ca2+ fluxes across the membrane 
and calmodulin activity.49 This suggests a role for CaZ+/calmodulin-dependent 
kinases, as was described above. Furthermore, as many agonists like PHE and 
ET-1 also stimulate contraction of cells in culture, part of the hypertrophy caused 
by these agonists might be induced by increased contraction, as suggested by the 
Ca2+ dependence of many of the intracellular events. 
Genetic Reprogramming During Cell Growth 
As described above, induction of cell growth results in induction or increase 
in transcription of several  gene^.^.^ These agonist- or stretch-induced alterations 
in cardiomyocyte phenotype are reminiscent of the changes during in vivo cardiac 
remodeling following cardiac overload. These changes lead to reexpression of fetal 
genes, e . g . ,  P-myosin heavy chain, skeletal 0-actin and ANF. The reexpression of 
P-myosin heavy chain leads to a larger amount of the homodimer V1 isomyosin 
and results in a slower rate of ATP cycling by myosin and thus a lower rate of 
contraction in the hypertrophied heart. On the other hand, this improves efficiency 
and economy of contraction, suggesting an adaptive response. 
It is important to stress that in the in vivo situation, enzymes that take part in 
Ca2 + homeostasis are also involved in phenotypic changes of the hypertrophied 
heart. For instance, the sarcoplasmatic reticulum Ca2+ ATPase as well as its 
regulatory protein phospholamban are not induced or may even be downregulated 
during development of hypertrophy, resulting in aberrant Ca2+ handling in the 
hypertrophied heart impairing r e l a x a t i ~ n . * ~ . ~ ~  
Differences in Signal Transduction and Magnitude of Hypertrophy between Agonists 
That Activate the PI Cycle 
Only a limited number of studies have directly compared signal transduction 
and induction of hypertrophy of agonists that activate the PI cycle. Using the 
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model of cultured neonatal rat ventricular myocytes we therefore compared the 
effects of AngII, ET-1 and the a,-adrenergic agonist phenylephrine (PHE). Al- 
though the second messenger inositol(1,4,5)tri~-phosphate was not detectable due 
to fast depho~phoryla t ion ,~~ ET-1 and PHE were equipotent in activation of the 
PI cycle, but the ET-1-induced production of inositol phosphates was subject to 
homologous desen~i t iza t ion .~~ The stimulation of the PI cycle by AngII is only 
very weak and transient.66 On the other hand, the increase in diacylglycerol level 
was highest after stimulation with AngII (unpublished data), suggesting that phos- 
pholipase D was activated in this case as well, as was observed earlier.69 Although 
cultured cardiomyocytes contain phorbol ester-stimulatable protein kinase C, di- 
rect activation of the kinase by the agonists was only very weak (results not 
shown). However, activation of other kinases is plausible as shown by the phos- 
phorylation of a 30-kDa nonrnembrane-bound protein by PHE but not by either 
ET-1 or AngII or by stimulation with phorbol ester.84 Noting these large differ- 
ences in signal transduction it is not surprising to see that the ultimate hypertrophic 
response was not the same for the three agonists. ET-1 is the strongest inductor 
of hypertrophy as judged by protein/DNA ratio, closely followed by PHE. In 
contrast, AngII gave only a very weak hypertrophic response.59 Agonist-induced 
induction of hypertrophy was already apparent after 24 hrs, in contrast to the 
effect of protein kinase C activation by phorbol ester where the proteidDNA 
ration was only increased after 48 hrs. The differences in ability to induce hypertro- 
phy were also found when induction of transcription of the immediate genes c- 
fos, c-jun, c-myc and EGR-1 was studied. Furthermore, the well-known induction 
of fetal gene expression, illustrated by expression of the ANF gene, was again 
weakest after stimulation with AngII. Experiments where the effect of hypertro- 
phy on the expression is studied of proteins involved in Ca2+ homeostasis were 
performed, and remarkable similarity with the effect of in vivo induction of hyper- 
trophy was noted, especially in the case of sarcoplasmatic reticulum Ca2+- 
A T p a ~ e . ~ ~  These results indicate that induction of hypertrophy of cardiomyocytes 
in culture is a good model for studying signal transduction and genetic repro- 
gramming. 
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